Lotfi Benboubker

2 Boulevard De Tonnelle
Tours, 37000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Spinal manifestations of diffuse large B-cell lymphoma.

Spinal manifestations of diffuse large B-cell lymphoma.

Journal: The spine journal : official journal of the North American Spine Society

Published: September 19, 2024

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.

Journal: The Lancet. Oncology

Published: April 05, 2024

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.

Journal: EJHaem

Published: May 16, 2023

Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.

Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.

Journal: Future oncology (London, England)

Published: May 03, 2023

Multiple Myeloma Spinal Lesion Care: Management of a Primary Bone Malignancy Rather Than a Spinal Metastasis.

Multiple Myeloma Spinal Lesion Care: Management of a Primary Bone Malignancy Rather Than a Spinal Metastasis.

Journal: World neurosurgery

Published: January 24, 2023

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.

Journal: Annals of hematology

Published: January 20, 2023

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

Journal: Blood cancer journal

Published: October 03, 2022

Spinal lesions in multiple myeloma: Primary bone tumors with distinct prognostic factors.

Spinal lesions in multiple myeloma: Primary bone tumors with distinct prognostic factors.

Journal: Surgical oncology

Published: September 30, 2022

Teclistamab in Relapsed or Refractory Multiple Myeloma.

Teclistamab in Relapsed or Refractory Multiple Myeloma.

Journal: The New England journal of medicine

Published: June 06, 2022

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.

Journal: Haematologica

Published: December 22, 2021

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.

Journal: Haematologica

Published: December 06, 2021

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.

Journal: Leukemia

Published: July 01, 2021

Showing 1-12 of 57

Last Updated: 09/26/2026